Keywords: Biotin, Mylan, Actavis, Biosimilar insulins, Sanofi, Lantus, Lilly, Humalog, Novo Nordisk, NovoLog

Mylan extends deal with Bioton to biosimilar insulins, as Actavis pulls out of JV

Article | 14 February 2013

Print This

US generic drugmaker Mylan (Nasdaq: MYL) said yesterday that it has entered into a definitive agreement with Polish biotech company ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in